Introduction {#s1}
============

The purpose of a clinical trial is to determine the benefits and harms of an intervention. This determination is made by measuring the effects of different treatments on outcomes. The selection of appropriate outcomes, therefore, is crucial to the assessment of whether one intervention is better than another. This review relates to studies that explain how outcomes have been selected for use in clinical trials in children younger than 16 years of age. For the purposes of this review we define children by age rather than by the literal meaning of offspring.

What Outcomes Measure---The Impact of Illness on a Patient\'s Life {#s1a}
------------------------------------------------------------------

Models have been developed that describe the effects of a disease on a patient, for example the biopsychosocial model and the World Health Organisation framework of impairment, disability, and handicap \[[@pmed-0050096-b001],[@pmed-0050096-b002]\]. Although these models differ in many ways, an underlying theme is that illnesses affect more than one aspect of a patient\'s life. For example, asthma may affect a child\'s life by way of troublesome daily symptoms even when the child is "well," exacerbations, disrupted school attendance, and abnormal lung function. Each of these effects of asthma on the child\'s life is potentially amenable to improvement after starting an intervention. In clinical trials, the extent to which an intervention affects the impact of an illness on a patient\'s life is reflected by measuring change in outcomes.

For the purpose of this review, we clarify our terminology in [Table 1](#pmed-0050096-t001){ref-type="table"}.

###### 
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Outcomes can reflect various effects of an intervention. They may directly measure a definitive clinical change, such as death or hospital admission. Surrogate outcomes, which are sometimes used in lieu of a definitive clinical outcome, aim to capture the effects of an intervention without having to wait for the clinical change to actually occur. In other words, they are proximal to the clinical outcome on the disease pathway, so a change can be detected sooner. They may be a measure of intermediate health status, which may be used to predict future health status; for example, glycosylated haemoglobin is used as a measure of current disease control in patients with diabetes mellitus, and has been shown to be a useful predictor of future control \[[@pmed-0050096-b003]\]. A surrogate outcome may even be an assumed or established risk factor that actually impacts on disease progression; for example, neonatal intraventricular haemorrhage, which is a recognised complication of prematurity, is thought to alter brain development in the early stages of life and predispose babies to developmental problems in childhood. There are validation criteria that should be fulfilled before a surrogate outcome can be confidently used in place of a definitive clinical outcome in clinical trials \[[@pmed-0050096-b004]\].

An outcome domain may be represented by a variety of outcomes. The domain of health care utilisation, for example, may be reflected by number of visits to a general practitioner, number of hospital admissions, or days spent in hospital. Conversely, outcomes may be relevant to more than one domain. For example, in clinical trials of children with asthma, the outcome "number of courses of rescue prednisolone therapy" may be a measure of health care utilisation, or could alternatively represent change in the domain "exacerbations." These various "levels" of outcome measurement are illustrated schematically in [Figure 1](#pmed-0050096-g001){ref-type="fig"}.

![Levels of Outcome Measurement](pmed.0050096.g001){#pmed-0050096-g001}

Selecting Outcomes for Use in Clinical Trials {#s1b}
---------------------------------------------

Clinical trials are "only as credible as their outcomes" \[[@pmed-0050096-b005]\], so when designing a clinical trial, the decision as to which outcomes should be measured is crucial. The selection of inappropriate outcomes can lead to wasted resources or misleading information that overestimates, underestimates, or completely misses the potential benefits of an intervention. Examples of these problems are well documented \[[@pmed-0050096-b006],[@pmed-0050096-b007]\]. Investigators can select from a range of several potential outcomes spanning different domains when they are designing a clinical trial, however, and the process of determining which outcome to use can be complex. The difficulty of selecting the most appropriate outcomes for use in a clinical trial is reflected in the fact that in several fields of clinical research there is much heterogeneity between clinical trials of specific diseases regarding exactly which outcomes to select \[[@pmed-0050096-b008],[@pmed-0050096-b009]\]. Some of the factors underlying this uncertainty may be that for these conditions there is uncertainty about which outcome domains are most relevant to patients, that the performance characteristics of potential outcomes have not been established, or that as the general care of patients has improved, previously used outcomes are no longer relevant.

Since the late 1980s there have been attempts, notably in the field of rheumatology (Outcome Measures in Rheumatology, <http://www.omeract.org/>), to develop "core sets" of outcomes that should be measured in all clinical trials of specific conditions. These studies generally use techniques to ascertain a consensus opinion from clinical experts as to which outcomes are most suitable for use in clinical trials. The three commonly used consensus techniques are nominal group technique (NGT), which entails structured face-to-face discussion with the aim of developing a solution to a specific problem, followed by a vote on the issue; Delphi technique, in which opinions are sought from individuals and the collated results are fed back to the group as a whole, to generate further discussion and finally reach an agreement; and semistructured discussion based around broader discussion points.

The objective of this project was to systematically review studies that address the process of selecting which outcome domains or outcomes to measure in clinical trials in children under 16 years of age. We have restricted this review to studies in children for the following reasons. In clinical research there is increasing recognition that children are not merely "small adults," and the methodology of conducting research in a paediatric population should be tailored accordingly. We anticipate that one way of determining which outcomes to use, in addition to the consensus techniques described above, may be to ascertain the opinions of both children and their parents regarding what they think are important aspects of their disease. This process poses unique challenges that may not be relevant when conducting similar research in adults with a particular condition, so it is appropriate to specifically review studies pertaining to outcome domain and outcome selection in clinical trials in children.

Methods {#s2}
=======

Study Selection {#s2a}
---------------

### Included studies. {#s2a1}

We decided that the following types of studies would be eligible for inclusion in the review: (1) Studies that develop or apply methodology for selecting outcome domains or outcomes to be used in clinical trials in children younger than 16 years of age, and (2) systematic reviews of these articles.

### Excluded studies. {#s2a2}

We excluded the following types of studies. (1) Studies that do not specifically state that the outcomes are appropriate for use in a paediatric population. (2) Studies that discuss how to measure, rather than how to select, an outcome domain or outcome for use in clinical trials. This category includes studies discussing performance characteristics of outcomes or instruments for measuring them. (3) Studies relating to clinical trials that assess interventions given to adults by measuring outcomes in children, for example the selection of neonatal outcomes to assess care given to their mothers.

Identification of Studies {#s2b}
-------------------------

In December 2006 we searched Cochrane databases (no date restrictions), and in January 2007 we searched MEDLINE (1950 to 2006; <http://www.ovid.com/site/catalog/DataBase/901.jsp?top=2&mid=3&bottom=7&subsection=10>), CINAHL (1982 to 2006; <http://www.cinahl.com/>), and SCOPUS (1966 to 2006; <http://www.scopus.com/>). SCOPUS is a platform that enables the searching of several databases, including EMBASE, simultaneously. We used the following abbreviated search strategy: "Clinical trials" AND "Outcomes" AND "Children" AND "methodology". Details of the full search strategy are included in [Table S1](#pmed-0050096-st001){ref-type="supplementary-material"}.

The abstracts produced by the searches were initially screened twice by one reviewer. The full texts of all potentially relevant articles were obtained, and these were assessed with regard to the eligibility criteria. Data were extracted from the studies that met all the eligibility criteria.

A second reviewer, who was blinded to the first reviewer\'s assessment of the abstracts, independently screened a database of abstracts that comprised all the abstracts for which the first reviewer obtained full text, plus a selection of abstracts rejected at the initial screening stage by the first reviewer. The purpose of this approach was to check the sensitivity of the initial screening process that had been performed in full by the first reviewer. A sample, rather than the complete set, was selected due to resource constraints. Any disagreements between the reviewers were resolved by discussion.

This process led to a list of studies for which full text were obtained. Both reviewers then scrutinised these articles for the predetermined inclusion and exclusion criteria in order to determine which studies should be included in the systematic review.

We then emailed a list of the studies we had identified to the Clinical Study Group (CSG) members of the Medicines for Children Research Network (MCRN) and asked if they knew of any other relevant studies, published or unpublished, that should be included. The CSG constitutes a multidisciplinary group of clinical experts with a strong interest in the planning of clinical trials within their specialities.

Data Extraction {#s2c}
---------------

The following data were extracted by one reviewer (IS) and checked independently by the second reviewer (LJ): (1) Condition for which the outcome domains or outcomes are discussed; (2) Description of the method; (3) People involved in selecting outcome domains or outcomes; (4) Outcome domains or outcomes selected; (5) The geographical setting of the collaborations, ascertained either by reading the text or, where listed, the names and institutions of people involved in the collaborations; (6) Limitations of the method as defined by the authors

Assessment of Methodological Quality {#s2d}
------------------------------------

The methodological quality of the studies was assessed by one author (IS). If a study developed or used methodology to select an outcome domain or an outcome, the article was assessed in terms of whether the method was described in sufficient detail to allow a reader to utilise it.

If a study described a consensus procedure, the following points were noted: (1) Is the selection process and areas of expertise of the participants described?; (2) Is the process of coming to consensus described in detail?

We searched for a validated assessment tool for critically appraising consensus statements but we could not identify one. We therefore asked two experts, one with experience of qualitative research and the other with experience of participating in a consensus statement exercise to advise on this methodological assessment checklist.

For systematic reviews of studies which used methodology for selecting outcomes it was agreed that we would use the Critical Appraisal Skills Programme Systematic Review Appraisal tool for assessing their methodological quality (<http://www.phru.nhs.uk/Pages/PHD/resources.htm>).

Data Analysis and Presentation of Results {#s2e}
-----------------------------------------

For synthesis of data we described the studies narratively and tabulated their characteristics. Consistent with the nature of the data, the results are presented in textual format.

Results {#s3}
=======

Description of Studies {#s3a}
----------------------

The initial database search identified 8,889 potentially relevant abstracts, of which 70 articles were retrieved in full and, finally, 25 included in the full review, as depicted by the flowchart in [Figure 2](#pmed-0050096-g002){ref-type="fig"}.

![Study Flowchart](pmed.0050096.g002){#pmed-0050096-g002}

In total, 57 full-text articles were reviewed and subsequently excluded. Of the 57 studies 19 were excluded because the authors did not use methodology for selecting outcomes (e.g., a review article based on personal opinion), 18 because the study related to how to measure outcomes rather than which ones to select, ten because the study made no mention of outcome selection, six because the study did not specifically state that the outcomes which were selected were relevant to children, and four that described consensus statements relating to clinical practice rather than clinical trial design. The reasons for exclusion of each individual study are presented in [Table S2](#pmed-0050096-st002){ref-type="supplementary-material"}.

In addition, 13 specific articles were suggested by the members of the MCRN CSGs in response to our email query. One of these articles summarised the work of a collaboration that had been identified by the literature search but did not describe the methodology used by the group in sufficient detail to warrant inclusion in the full review, so is added as an additional reference \[[@pmed-0050096-b010]\]. The other studies identified were not deemed to be eligible for the full review.

Agreement between Reviewers {#s3b}
---------------------------

The second reviewer was provided with a database of 100 abstracts. These included 70 for which the first reviewer thought full text should be retrieved, and a randomly selected sample of 30 abstracts that had been excluded by the first reviewer at the abstract screening stage.

The second reviewer agreed that all 30 abstracts rejected at the abstract screening stage were appropriately excluded by the first reviewer.

Of the 70 abstracts for which full text was obtained by the first reviewer, the second reviewer agreed with 61, and disagreed with nine. After discussion it was agreed that all nine should be retrieved in full based on the abstract. Of these, eight were excluded after reading the full text and one was included.

Following full text review there was complete agreement between the second and first reviewer about the 25 included and 45 excluded abstracts. The second reviewer also checked all the data that had been extracted by the first reviewer, and agreed completely with the tabulated characteristics of the studies.

Included Studies {#s3c}
----------------

The 25 articles included in the full review represented the work of 13 collaborative groups. The characteristics of each study are included in [Table S3](#pmed-0050096-st003){ref-type="supplementary-material"}, and summarised in [Table 2](#pmed-0050096-t002){ref-type="table"}.

###### 
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Six of these groups (Griffiths et al. \[[@pmed-0050096-b011]\], Ramsey et al. \[[@pmed-0050096-b012]\], Pavletic et al. \[[@pmed-0050096-b013]\], Giannini et al. \[[@pmed-0050096-b014]\], International Myositis Assessment and Clinical Studies group (IMACS) \[[@pmed-0050096-b015]\], and Paediatric Rheumatology International Trials Organisation (PRINTO) \[[@pmed-0050096-b016]\]) aimed to develop a consensus statement specifically about outcome measures that should be used in clinical trials of certain medical conditions. Five groups (Carlson et al. \[[@pmed-0050096-b017]\], Goldstein et al. \[[@pmed-0050096-b018]\], LaFrance et al. \[[@pmed-0050096-b019]\], Neonatal Drug Development Initiative (NDDI) \[[@pmed-0050096-b020]--[@pmed-0050096-b024]\], and West Delphi group \[[@pmed-0050096-b025]\]) discussed which outcomes to measure as part of workshops which addressed wider clinical trial design issues. One group (Smith et al. \[[@pmed-0050096-b026]\]) aimed to ascertain the opinions of clinical experts about which outcomes to measure in clinical trials in children with asthma. One group (DeRouen et al. \[[@pmed-0050096-b027]\]) ascertained the opinions of experts about which outcome to measure in a specific safety trial of two interventions used in paediatric dental restoration. Our search identified no systematic reviews of studies that had selected outcome measures for use in clinical trials.

Most groups appeared to comprise an international collaboration of participants. Eight groups were based in the US (Ramsey et al. \[[@pmed-0050096-b012]\], Goldstein et al. \[[@pmed-0050096-b018]\], La France et al. \[[@pmed-0050096-b019]\], the NDDI \[[@pmed-0050096-b020]--[@pmed-0050096-b024]\], Carlson et al. \[[@pmed-0050096-b017]\], Griffiths et al. \[[@pmed-0050096-b011]\], DeRouen et al. \[[@pmed-0050096-b027]\], and Pavletic et al. \[[@pmed-0050096-b013]\]). One group was based in Europe (West Delphi group \[[@pmed-0050096-b025]\]). One group was based in Australasia (Smith et al. \[[@pmed-0050096-b026]\]). The three rheumatology collaborations \[[@pmed-0050096-b014]--[@pmed-0050096-b016]\] seem to have been based mainly in the US, but it appears that many of the leaders of these groups were based in Europe.

Methodological Quality of Studies {#s3d}
---------------------------------

General observations regarding the methodological quality of the studies are provided in this section. Methodological features of each specific study are provided in [Table S4](#pmed-0050096-st004){ref-type="supplementary-material"}.

### Reporting of methodology. {#s3d1}

Of the 13 collaborations four used structured techniques to formulate a consensus (Giannini et al. \[[@pmed-0050096-b014]\], West Delphi group \[[@pmed-0050096-b025]\], PRINTO \[[@pmed-0050096-b016]\], and IMACS \[[@pmed-0050096-b015]\]); these were NGT and/or Delphi technique. Of these groups, three described the process very clearly. Eight collaborations came to a consensus by structured discussion, but without using structured consensus formulation techniques mentioned above (Goldstein et al. \[[@pmed-0050096-b018]\], Ramsey et al. \[[@pmed-0050096-b012]\], LaFrance et al. \[[@pmed-0050096-b019]\], NDDI \[[@pmed-0050096-b020]--[@pmed-0050096-b024]\], Carlson et al. \[[@pmed-0050096-b017]\], Griffiths et al. \[[@pmed-0050096-b011]\], De Rouen et al. \[[@pmed-0050096-b027]\], and Pavletic et al. \[[@pmed-0050096-b013]\]). All of these groups described the discussions in some detail. One group sought opinions in a questionnaire-based survey, and the methodology used for this study was described in sufficient detail to be able to repeat the study (Smith et al. \[[@pmed-0050096-b026]\]).

### Selection of participants. {#s3d2}

All groups described the background of their participants. Only two of these groups described in detail the process by which it was decided specifically which individuals would be involved (West Delphi group \[[@pmed-0050096-b025]\] and Smith et al. \[[@pmed-0050096-b026]\]).

Methods Used to Select Outcomes {#s3e}
-------------------------------

The following techniques were used to ascertain expert opinion concerning which outcomes ought to be measured in clinical trials of children with specific conditions.

### Delphi technique. {#s3e1}

As described earlier, Delphi technique is one method of reaching a consensus opinion that relies on one person collating the views of each individual in a group, collating the results, and feeding these back to the whole group \[[@pmed-0050096-b028]\]. Statements made by participants at each stage of the process can be used to formulate the next round of questions. This technique has been used since the 1950s. Three groups utilised this method as follows.

The West Delphi group \[[@pmed-0050096-b025]\] used this technique to develop a core set of outcomes for use in clinical trials of children suffering from infantile spasms. The whole process was conducted by email over six rounds. In round one a group of 133 invited participants, of which 42 responded, were asked multiple-choice questions covering various aspects of clinical trial design, including outcomes. In round two a separate set of multiple-choice questions was provided, having fed the results of round one back to the group. At this stage the participants were also invited to comment and provide their personal opinions regarding outcomes. In round three statements were formulated from those responses in rounds one and two that had represented majority opinion. Participants were invited to respond as to whether they agreed or disagreed with these statements. For round four the statements were modified, and participants commented on their suitability and content. Rounds five and six consisted of formulation of a draft and, subsequently, a final paper that were altered following comments from the group.

The IMACS \[[@pmed-0050096-b015]\] group used a Delphi technique to develop a core set of outcome domains and outcomes for use in clinical trials in children with inflammatory myopathy. The actual process itself is not described in detail in the article, but authors stated that the group consisted of "more than 100" members.

The PRINTO \[[@pmed-0050096-b016]\] group used a Delphi technique over two sequential questionnaire-based surveys to identify which variables should be measured in clinical trials of children with SLE. In the first questionnaire they asked 267 participants to indicate up to ten variables they judged as clinically most important. In the second questionnaire, the facilitators listed those indicators that had been suggested by at least ten responders, and asked the participants to rank in order their top ten choices.

### Nominal group technique. {#s3e2}

NGT is a technique based on structured face-to-face discussion developed in the early 1970s. Having discussed a problem, with a view to providing potential solutions, the participants vote on the options presented, and ultimately a consensus is reached \[[@pmed-0050096-b029]\]. Two groups utilised this technique.

PRINTO \[[@pmed-0050096-b016]\] used NGT to discuss specific issues regarding the potential outcomes identified by the initial Delphi technique discussions described earlier. The NGT exercise had five objectives, which were tackled by a group of 40 participants: (1) to classify the proposed outcomes into "domains"; (2) to classify the outcomes into "concepts of disease activity"; (3) to select the outcome domains that should be measured in clinical trials; (4) to select the outcomes that should be used to measure these domains; and (5) to discuss specific design issues of the prospective validation phase of the study.

Giannini et al. \[[@pmed-0050096-b014]\] used NGT to select from a set of potential outcomes a preliminary core set of six. The process used is not described in further detail in the study. The initial list of potential outcomes had been identified by sending a questionnaire to a 16-member advisory council.

### Semistructured discussion. {#s3e3}

Most groups did not use structured techniques of consensus development such as Delphi or NGT, but rather came to consensus by discussion at meetings or workshops. As mentioned earlier, some collaborations---for example those groups discussing methodology issues in studies of neonates---discussed outcome selection broadly, as part of wider discussions about neonatal clinical trial designs. Other groups---for example, the group selecting outcome measures for use in an individual clinical trial of dental restoration---conducted very focussed discussions about very specific problems.

### Questionnaires. {#s3e4}

Smith et al. \[[@pmed-0050096-b026]\] sent questionnaires to 39 health care professionals and researchers with expertise in asthma to ask which outcomes they would use for a variety of clinical, research, and public health scenarios, including questions about which outcome they would use in clinical trials of acute and preventative asthma medication. Three groups (Giannini et al. \[[@pmed-0050096-b014]\], West Delphi \[[@pmed-0050096-b025]\], and PRINTO \[[@pmed-0050096-b016]\]) used questionnaires as part of the process of ascertaining the opinions of experts, mainly in the preliminary phases of the consensus process.

People Involved in Selecting Outcomes {#s3f}
-------------------------------------

### Clinical experts. {#s3f1}

All 13 groups included people with clinical expertise in the fields for which they were selecting outcomes. Eight groups specifically mention the involvement of clinicians in both paediatric and adult health care.

### Research experts. {#s3f2}

All groups appeared to include members who were experienced in research in the clinical condition for which outcomes were being selected. In addition to these clinical research experts, some groups also included biostatisticians and epidemiologists. Three groups involved experts from other clinical research areas who had experience in collaborations that had selected outcomes for clinical trials of other medical conditions. More collaborations may have used experts from this category, but may have referred to them generically as "research experts," so it is difficult to quantify exactly how many groups used this approach.

### Patients or parents. {#s3f3}

Three groups ascertained the opinions of parents of children with medical conditions as to which outcomes they thought should be measured, but no group involved children directly. IMACS \[[@pmed-0050096-b015]\] involved two patient support group leaders who had a child who suffered from inflammatory myopathy. Although this was not explicitly stated in the text, we elicited this information by searching for the names of the support group leaders on an internet search engine. Carlson et al. \[[@pmed-0050096-b017]\] also involved "representatives of families with affected children" in their discussions about outcomes in clinical trials of children with bipolar affective disorder. Pavletic et al. \[[@pmed-0050096-b013]\], at the end of their report, acknowledge "patients and patient and research advocacy groups." The level of involvement of these people was not described in detail in any of these articles.

### Industry and drug regulatory authority representatives. {#s3f4}

Three groups (Carlson et al. \[[@pmed-0050096-b017]\], Ramsey et al. \[[@pmed-0050096-b012]\], and the NDDI \[[@pmed-0050096-b020]--[@pmed-0050096-b024]\]) specifically mention that representatives from industry or the Food and Drug Administration (FDA) were present. The NDDI is described as a collaboration between the FDA and "neonatal experts and colleagues, representing industry and academia" \[[@pmed-0050096-b010]\]. Carlson describes invited participants in the group selecting outcomes for clinical trials of children with bipolar disorder as including "pharmaceutical industry sponsors with an interest in mood stabilizer products, staff of the FDA and their counterparts from regulatory agencies in Canada and the European Union" \[[@pmed-0050096-b017]\]. The Cystic Fibrosis Foundation sponsored a consensus conference that also included "representatives from both the Cystic Fibrosis Foundation and the U.S. Food and Drug Administration" \[[@pmed-0050096-b012]\].

Techniques Used to Validate Outcomes {#s3g}
------------------------------------

Three groups made some attempt to validate the outcomes they had selected.

Giannini et al. \[[@pmed-0050096-b014]\] assessed the multicollinearity and redundancy of a core set of outcomes for use in clinical trials of children with rheumatoid arthritis by measuring them in a group of children in a clinical practice setting, and using a database from a previous observational cohort study. The acceptability of the core set of outcomes to a wider group of clinicians was assessed by sending a questionnaire to an international selection of rheumatologists seeking their reactions to the outcomes.

The IMACS group retrospectively assessed the validity, reliability, and responsiveness of the outcomes they had selected by reviewing available literature on the topic \[[@pmed-0050096-b015]\].

The PRINTO group prospectively validated the core set of outcomes they had produced for clinical trials of children with SLE \[[@pmed-0050096-b030]\]. This was done by measuring the outcomes in patients in a clinical out patients setting who were being started on new modalities of treatment for their condition. In this way the authors aimed to "mirror" a clinical trial setting. The feasibility, discriminative ability, validity, and internal consistency of the core set of outcomes were assessed in this way.

All three of these groups also developed "definitions of improvement," based on the degree of change within each outcome, which could be used as a dichotomous index in clinical trials to determine whether patients had benefited from the treatment they had received. This was done in all cases by developing a set of "paper patient profiles," and asking a group of experts whether or not they thought the patient had improved. A set of potential definitions of improvement was then narrowed down to a final definition by way of consensus formation techniques.

Which Outcomes Were Selected by the Groups? {#s3h}
-------------------------------------------

In [Table S5](#pmed-0050096-st005){ref-type="supplementary-material"} we summarise the outcomes that were selected by each group, categorised into the following outcome domains: disease activity; disease complications; adverse effects of therapy; functional status; social outcomes, family outcomes and Quality of Life; resource utilisation.

Discussion {#s4}
==========

To our knowledge this is the first systematic review of studies that addressed selection of outcomes for use in clinical trials in children.

We identified 13 groups formed to address the issue of selecting outcomes for use in paediatric clinical trials. Certain groups---notably, those who have selected outcomes for clinical trials of children with rheumatological conditions---have specifically highlighted that it is inappropriate simply to use the outcomes utilised in adult clinical trials in a paediatric population.

We identified three methods used for reaching consensus, namely NGT, Delphi technique, and semistructured discussion. Many groups used a multidisciplinary approach to the problem of outcome selection, including researchers with experience of clinical trial design, statisticians, and clinicians. Some groups also involved representatives from industry or drug regulatory authorities, but the nature of their involvement is not evident from reading the reports.

No group among the studies we reviewed directly involved children in the process of selecting outcomes. As the aim of clinical trials should be to determine whether patients experience important benefits from an intervention, it was notable that we did not identify any studies that had directly asked children what they considered to be the most relevant outcome domains or outcomes. In the United Kingdom steps are being taken to involve consumers in medical research. A major initiative is the James Lind Alliance (<http://www.lindalliance.org/>), a collaboration with the aim of ascertaining from patients what they think are the most pressing research priorities for various conditions. Determining appropriate outcomes for paediatric studies is thus another area in which consumer involvement in clinical trial design should be encouraged. The difficulties of undertaking this task, however, should not be underestimated \[[@pmed-0050096-b031]\].

Robustness and Limitations of the Review {#s4a}
----------------------------------------

Our review was conducted in a rigorous, systematic manner. Two reviewers adhered to strict eligibility criteria to determine which studies should be included. Although the sample of excluded papers checked by the second reviewer represented a small proportion of all the ineligible studies, we concluded that agreement between the reviewers was adequate. We determined that a smaller proportion of excluded studies would be sufficient for quality assurance as compared to a review in which we were meta-analysing the results of clinical trials; possible missed studies were considered an acceptable tradeoff.

There were recurring features of the methodology and reporting quality of the consensus statements that may have compromised the scientific validity of the studies we identified. Most studies that described formation of a consensus statement did not explain in sufficient detail two key aspects of the process---namely, the method used to select group participants, and the process by which consensus was reached. Insufficient information was given to determine the level of involvement of certain groups involved in the research, particularly industry representatives, drug regulatory authority representatives, and parents of affected children.

Although the 8,889 abstracts identified were screened twice, it may be possible that some relevant studies were missed. The types of studies that may not have been identified at this stage include clinical trials that did not describe in the abstract how the authors selected their outcomes, but subsequently in the full text may have mentioned the process used. It is also possible that some studies may have been missed by not searching the "grey" literature such as unpublished conference proceedings.

We excluded studies that did not state specifically that they selected outcomes for use specifically in clinical trials in children. Our reason for this exclusion was that such studies should involve patients themselves, and the unique challenges of doing this in children warrants the separation of adult and paediatric studies. Another group of studies excluded were those concerned with the development of assessment tools for outcomes such as quality of life. Although this work is crucial for designing valid assessment tools, and will to some degree ascertain from children how illness affects their life, these studies focussed on how to measure an outcome rather than what outcome to measure.

Another set of studies outside the scope of this review were those relating to the selection of outcomes that are measured in newborns as a surrogate measure of maternity care given to women. For example, one way of evaluating the efficacy of antenatal care is to measure outcomes in babies such as rates of neonatal infection \[[@pmed-0050096-b032]\]. Similarly, studies in which outcomes were selected that evaluate the effect of interventions given to children by measuring effects on the family were not systematically sought. We did, however, identify two studies in which such outcomes were selected \[[@pmed-0050096-b019],[@pmed-0050096-b033]\].

Core Outcomes {#s4b}
-------------

If implemented, the studies we have identified should reduce the impact of inappropriate outcome selection on the quality of the evidence provided by individual clinical trials. The development of a universally agreed core set of outcomes for a condition could, as well as improving the quality of individual clinical trials, lead to less heterogeneity between trials. One problem associated with nonuniform reporting of outcomes is outcome reporting bias, a phenomenon that results from the selective reporting of some outcomes but not others, depending on the results \[[@pmed-0050096-b034],[@pmed-0050096-b035]\].

One cause of outcome reporting bias may be that statistically insignificant results are more likely to be left out of the report, so outcomes at the planning stage of a trial that might otherwise have been deemed clinically relevant are deemed "irrelevant" after data analysis, rendering the published literature a biased and selective representation of the research \[[@pmed-0050096-b036]\]. Disease-specific, universally agreed core sets of outcomes that should be measured and reported in all clinical trials of a specific condition, regardless of statistical significance, have been advocated as a solution to this common problem \[[@pmed-0050096-b035]\]. Uniform selection of outcomes would also make interpretation of results and comparison across trials simpler, hence making meta-analyses easier and more powerful \[[@pmed-0050096-b009]\].

European Drug Regulation {#s4c}
------------------------

It is increasingly recognised that there is a need for high-quality paediatric clinical trials, and the development of Paediatric Investigation Plans (PIPs) is one of the changes in drug regulation in Europe that should facilitate this goal. The PIP is a detailed outline of the research, submitted to the European Medicines Agency (EMEA), that would be needed to investigate the potential benefits and harms of medications for use in children. If a drug company were to be involved in the writing and implementation of a PIP, they would be eligible for marketing rewards in the form of prolonged patent protection and market exclusivity. When a PIP is submitted, the endpoints selected for the trial must be clearly stated and their appropriateness described (<http://www.emea.europa.eu/htms/human/paediatrics/pips.htm>). The studies we have identified that suggest to trialists which outcomes to measure should be of use to people designing a PIP, and it is possible that the types of studies we have identified may become more popular as drug companies seek to take advantage of the benefits of conducting high-quality clinical trials.

The new standards for conducting clinical trials of investigational medicinal products set by the EMEA aim to improve the quality of paediatric research. In order to obtain a license for a drug, it must be investigated according to these guidelines <http://www.emea.europa.eu/htms/human/humanguidelines/efficacy.htm>). In July 2007, of the 13 paediatric conditions identified in this review the EMEA Web site included guidelines for one (juvenile idiopathic arthritis) and a concept paper discussing the need for guidelines for another (cystic fibrosis).

The Selection of Outcomes for Use in Children {#s4d}
---------------------------------------------

It is appropriate that some aspects of study design in clinical trials in children differ from equivalent studies performed in adults, and selection of outcomes is one such issue that trialists should consider. In certain situations outcome selection may be similar between the two groups, and some outcomes could be appropriately transposed from adult studies into trials in paediatric populations either in their original state or with slight modification. The danger, however, of not acknowledging the differences between children and adults with the same disease is that the overall validity of trial results could be compromised. Griffiths et al. \[[@pmed-0050096-b011]\], when discussing which outcomes to measure in clinical trials of children with Crohn disease, highlight that the importance of linear growth is "unique to pediatric patients." Another example of an outcome exclusive to children is the assessment of neurodevelopment. Other differences between adults and children that may preclude the use of the same outcomes for both groups include distinct disease pathogenesis, different clinical features and natural history, variations in physiological and psychological outcomes, and contrasting roles within the contexts of families and society in general that may preclude the use of the same outcomes.

Unanswered Questions {#s4e}
--------------------

The best strategy for selecting outcomes for clinical trials in children is currently not known, and future research in this area is warranted. One important question relates to the involvement of children and parents in the formulation of consensus statements. It seems logical that their involvement would help determine the most appropriate outcomes to measure, but there is no evidence to substantiate this hypothesis, nor is there a framework that could recommend the best strategy for involvement. Another area for research is the investigation of the relative strengths and weaknesses of the consensus formation techniques identified here when applied to the problem of selecting outcomes for paediatric studies.

In summary, we have reviewed studies that address the process of selecting outcomes for clinical trials in children. Although it is commendable that there are existing collaborations in several clinical areas, future work in this area may be improved by involving children and parents in the process. The studies identified by this review will go some way to improving the quality of paediatric research, but further research is justified and urgently needed.

Conclusions {#s4f}
-----------

### Implications for the practice of designing clinical trials. {#s4f1}

We identified 13 paediatric conditions for which work has been done to determine which outcomes should be measured in clinical trials. When designing clinical trials in these conditions, this work should make the selection of outcomes easier and more uniform.

### Implications for research. {#s4b2}

Although some work on how to select outcomes in paediatric trials has been published in a few clinical areas, there is a need for similar work to be conducted in other areas. Very little work has been done that involves parents or children in assessing which outcomes should be measured in clinical trials; future research should be undertaken to address this deficiency.

Supporting Information {#s5}
======================

###### Search Methods for Identification of Studies

(114 KB DOC)

###### 

Click here for additional data file.

###### Characteristics of Excluded Studies

(243 KB DOC)

###### 

Click here for additional data file.

###### Characteristics of Included Studies

(145 KB DOC)

###### 

Click here for additional data file.

###### Critical Appraisal of the Methodological Quality of Included Studies

(110 KB DOC)

###### 

Click here for additional data file.

###### Outcomes Selected for Use in Clinical Trials in Children

(156 KB DOC)

###### 

Click here for additional data file.

###### QUOROM Checklist

(41 KB DOC)

###### 

Click here for additional data file.
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CSG

:   Clinical Study Group

EMEA

:   European Medicines Agency

FDA

:   Food and Drug Administration

FEV1

:   forced expiratory volume in one second; GVHD graft-versus-host disease

IIM

:   idiopathic inflammatory myopathy

IMACS

:   International Myositis Assessment and Clinical Studies group

MCRN

:   Medicines for Children Research Network

NDDI

:   Neonatal Drug Development Initiative

NGT

:   nominal group technique

PIP

:   Paediatric Investigation Plan

PRINTO

:   Paediatric Rheumatology International Trials Organisation

SLE

:   systemic lupus erythematosus
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